Goldspan Health review
A single plan, a sublingual route for the needle-averse, and a billing cycle that quietly bills thirteen times a year.
Pricing last checked on Goldspan Health's own site .
- Semaglutide
- $229/mo (billed every 28 days, compounded)
- Tirzepatide
- $299/mo (billed every 28 days, compounded)
- Coverage
- All 50 states
- Brand-name
- Compounded only
The scorecard
Goldspan Health scored on our six published factors. See the methodology.
What we like
- One plan per molecule rather than a tiered ladder, so there is no prepay figure pretending to be a monthly rate
- Sublingual full-dose and microdose programs are sold alongside the injections for anyone avoiding needles
- The compounding class is disclosed as 503A or 503B on the therapy pages
- Three clinicians are named on the storefront that delivers the care, with their roles stated
- Prices are published before any account is created, and the renewal timeline is shown as a dated schedule
The caveats
- The hero prints a monthly price while the plan card says the order renews every 28 days — thirteen charges a year against a figure a reader will read as twelve
- Pause, delay and cancel at any time is promised on the storefront while the refund policy says all sales are final and the platform's own terms say a placed order cannot be canceled
- The seal displayed on the storefront certifies the storefront operator's own domain, not this brand's, so it is not evidence about Goldspan
- The homepage claims 50 states while the Terms say some therapies are unavailable in certain states, and which therapies in which states is never said
- Goldspan publishes no legal entity, address or governing law of its own, names no pharmacy, and its clinicians are attributed to a platform that says it is not a medical practice
The verdict
Best for: Someone who wants one plan rather than a ladder, and will read the renewal timeline before subscribing. A single plan, a sublingual route for the needle-averse, and a billing cycle that quietly bills thirteen times a year.
Ranked #133 of 539 providers we have reviewed — for comparison, read our ruling on CoreAge Rx, our #1 pick. In the ranking it sits between Get Thin MD at #132, 71/100 above and AlyveRx at #134, 71/100 below, with the Care Clinics ruling the next one down.
If that ruling leaves you undecided, the 7 programs we rank against Goldspan Health are graded on the same six factors and listed in score order.If you would rather start from the top of the field, our full board of 539 providers is the place to start if you are still shortlisting. We have also ruled on it directly: CoreAge Rx vs Goldspan Health goes to CoreAge Rx, 94/100 to 71/100.
Compare with other providers
The closest rulings to Goldspan Health by Verdict Score — the realistic shortlist if you are weighing this one up.
- #114TRYM Health— TRYM Health (TRYM) is a nationwide telehealth service offering compounded GLP-1 weight-loss medication — semaglutide (~$96/mo, $3.20/day) and tirzepatide (~$126/mo, $4.20/day) — as additive-free multi-dose…73/100
- #115VirtualCare2Go— VirtualCare2Go is a US telehealth provider offering compounded GLP-1 weight-loss medication with same-day visits and national shipping.73/100
- #116Zappy Health— Zappy Health is a telehealth weight-loss platform offering both compounded and brand-name GLP-1: compounded semaglutide from $159/month and tirzepatide from $299/month, plus brand Wegovy and Zepbound.73/100
- #117Pallas Health— Names its six dispensing pharmacies and two of its prescribing physicians with NPIs you can check — and sells no month-to-month plan at all, so the advertised “$199/mo average” is $597 charged every twelve weeks.70/100
- #118Revive Meds— The most transparent supply chain of the five and the least transparent pricing, with real costs held back until you have finished a health intake.72/100
- #119Arc-1— Arc-1 offers compounded semaglutide (from $249.99) and compounded tirzepatide (from $299.99) as per-dose purchases, not monthly subscriptions.72/100
Pricing, states and verification reflect Goldspan Health's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Goldspan Health's site. Not medical advice; see our disclosure.